Document is current
Any future updates will be listed below
-
Authors
DenAdel, Alan
Hughes, Madeline
Thoutam, Akshaya
Gupta, Anay
Navia, Andrew W.
Fusi, Nicolo https://orcid.org/0000-0002-4102-0169
Raghavan, Srivatsan https://orcid.org/0000-0002-5374-9918
Winter, Peter S. https://orcid.org/0000-0002-6557-3219
Amini, Ava P. https://orcid.org/0000-0002-8601-6040
Crawford, Lorin https://orcid.org/0000-0003-0178-8242
-
Funding
Funding for this research was provided by:
David and Lucile Packard Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA260442)
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 6 May 2026
First Online: 9 June 2026
Competing interests
: S.R. holds equity in Amgen. P.S.W. reports compensation for consulting/speaking from Engine Ventures, AbbVie and Passkey Therapeutics unrelated to this work. S.R. and P.S.W. receive research funding from Microsoft. M.H., N.F., A.P.A. and L.C. are employees of Microsoft and own equity in Microsoft. The other authors declare no competing interests.
